Onodera S, Otaki M, Oikawa K, Mikami M, Sato I
Tohoku J Exp Med. 1975 Aug;116(4):317-25. doi: 10.1620/tjem.116.317.
Fifteen cases of multiple myeloma and 6 cases of macroglobulin emia Waldenstrom were followed up from 1957 to 1974. As for administration of drugs a low continuous dose regimen was mainly employed instead of a high intermittent dose regimen. 50% survival time from the onset of the disease was 18 months for multiple myeloma and 25 months for macroglobulinemia Waldenstrom. 3 cases of multiple myeloma are still living 44 months after the onset of symptoms. Cyclophosphamide and melphalan seem to have contributed much to the prolonged survival of these patients as well as improved supportive care.
对15例多发性骨髓瘤患者和6例华氏巨球蛋白血症患者进行了1957年至1974年的随访。在药物治疗方面，主要采用低剂量持续给药方案，而非高剂量间歇给药方案。多发性骨髓瘤患者从发病起的50%生存时间为18个月，华氏巨球蛋白血症患者为25个月。3例多发性骨髓瘤患者在出现症状44个月后仍存活。环磷酰胺和美法仑似乎对这些患者的生存期延长以及支持治疗的改善起到了很大作用。
